DBVT News and Press, DBV Technologies S.A. From 08/01/19

Montrouge, France, August 1, 2019 DBV Technologies Reports First Half 2019 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported first half 2019 financial results. The inte...

AMF REGULATED INFORMATION Montrouge, France, July 18, 2019 Amendment to the DBV Technologies Liquidity Contract with NATIXIS ODDO BHF and Half-Year Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical...

Aimmune Therapeutics ( AIMT -6.5% ) is down on below-average volume on the heels of a cautionary report on peanut allergy treatments by the non-profit Institute for Clinical and Economic Review (ICER). More news on: Aimmune Therapeutics, Inc., DBV Technologies S.A., Healthcare stocks...

Gainers:  Oasmia Pharmaceutical OASM  +76% . Xenetic Biosciences (NASDAQ: XBIO ) +41% . Tyme Technologies TYME  +22% . Gol Linhas Aereas Inteligentes S.A. GOL  +19% . BIOLASE (NASDAQ: BIOL ) +16% . OHR Pharmaceutical (NASDAQ: OHRP ) +15% . Cool Holdings (NASDAQ: AWSM...

Oasmia Pharmaceutical AB (NASDAQ: OASM ) +51% . More news on: Oasmia Pharmaceutical AB (publ), Tyme Technologies, Inc., DBV Technologies S.A., Stocks on the move, Read more ...

Montrouge, France, June 26, 2019 DBV Technologies Announces Appointment of Pharis Mohideen, M.D., as Chief Medical Officer   Dr. Mohideen brings extensive experience in clinical drug development Dr. Hugh Sampson to continue serving as Chief Scientific Officer DBV Technol...

Montrouge, France, June 1, 2019 DBV Technologies to Present Data from Epicutaneous Immunotherapy at EAACI 2019 Data presented highlights potential long-term benefit of Viaskin ® Peanut   DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Sto...

Montrouge, France, May 24, 2019 DBV Technologies Announces Results of its 2019 Ordinary and Extraordinary General Meeting and the Appointment of Viviane Monges to the Board of Directors Shareholders approve all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR...

One, which I mention several times elsewhere, is the need for patience if big profits are to be made from investment. Put another way, it is often easier to tell what will happen to the price of a stock than how much time will elapse before it happens. The other is the inherently deceptive ...

DBV Technologies' (NASDAQ: DBVT ) Deputy CEO and Principal Financial Officer, David Schilansky, has decided to leave the company to pursue other professional opportunities. More news on: DBV Technologies S.A., DBV Technologies S.A., Healthcare stocks news, Read more ...